These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29267243)

  • 21. [Complement activation in citrate plasma--inhibitory effect of anticoagulants on serum complement activation].
    Kobayashi E; Kitano E; Kondo H; Kitamura H
    Rinsho Byori; 1999 Feb; 47(2):160-4. PubMed ID: 10097633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Different Anticoagulant Agents on Immune-Related Genes in Leukocytes Isolated from the Whole-Blood of Holstein Cows.
    Floridia V; Sfulcini M; D'Alessandro E; Cattaneo L; Mezzetti M; Liotta L; Trevisi E; Lopreiato V; Minuti A
    Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hirudin versus heparin for use in whole blood in vitro biocompatibility models.
    Bexborn F; Engberg AE; Sandholm K; Mollnes TE; Hong J; Nilsson Ekdahl K
    J Biomed Mater Res A; 2009 Jun; 89(4):951-9. PubMed ID: 18470919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of CTAD (citrate-theophylline-adenosine-dipyridamole) as a universal anticoagulant in dogs.
    Granat FA; Geffré A; Lucarelli LA; Braun JD; Trumel C; Bourgès-Abella NH
    J Vet Diagn Invest; 2017 Sep; 29(5):676-682. PubMed ID: 28673194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. UPLC-ESI-QTOF/MS and multivariate data analysis for blood plasma and serum metabolomics: effect of experimental artefacts and anticoagulant.
    Barri T; Dragsted LO
    Anal Chim Acta; 2013 Mar; 768():118-28. PubMed ID: 23473258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects of anticoagulants on the activation of platelets ex vivo.
    Schneider DJ; Tracy PB; Mann KG; Sobel BE
    Circulation; 1997 Nov; 96(9):2877-83. PubMed ID: 9386152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticoagulant-induced pseudothrombocytopenia and pseudoleucocytosis.
    Schrezenmeier H; Müller H; Gunsilius E; Heimpel H; Seifried E
    Thromb Haemost; 1995 Mar; 73(3):506-13. PubMed ID: 7545322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of hirudin as universal anticoagulant in haematology, clinical chemistry and blood grouping.
    Menssen HD; Melber K; Brandt N; Thiel E
    Clin Chem Lab Med; 2001 Dec; 39(12):1267-77. PubMed ID: 11798089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro.
    Xu Y; Wu W; Wang L; Chintala M; Plump AS; Ogletree ML; Chen Z
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):332-8. PubMed ID: 23348428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparin molecularly imprinted surfaces for the attenuation of complement activation in blood.
    Rosengren-Holmberg JP; Andersson J; Smith JR; Alexander C; Alexander MR; Tovar G; Ekdahl KN; Nicholls IA
    Biomater Sci; 2015 Aug; 3(8):1208-17. PubMed ID: 26222036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
    Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
    Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Importance of uniform heparin coating on biopolymers.
    Da Luz Moreira P; Wada ML; Novello WP
    Artif Organs; 2000 Mar; 24(3):209-11. PubMed ID: 10759643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant hirudin as an anticoagulant during cardiac operations: experiments in a pig model.
    Riess FC; Pötzsch B; Behr I; Jäger K; Rössing R; Bleese N; Schaper W; Müller-Berghaus G
    Eur J Cardiothorac Surg; 1997 Apr; 11(4):739-45. PubMed ID: 9151047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Temporal effects of 3 commonly used anticoagulants on hematologic and biochemical variables in blood samples from macaws and Burmese pythons.
    Harr KE; Raskin RE; Heard DJ
    Vet Clin Pathol; 2005 Dec; 34(4):383-8. PubMed ID: 16270264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein source and choice of anticoagulant decisively affect nanoparticle protein corona and cellular uptake.
    Schöttler S; Klein K; Landfester K; Mailänder V
    Nanoscale; 2016 Mar; 8(10):5526-36. PubMed ID: 26804616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticoagulants impact on innate immune responses and bacterial survival in whole blood models of Neisseria meningitidis infection.
    Strobel L; Johswich KO
    Sci Rep; 2018 Jul; 8(1):10225. PubMed ID: 29977064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measurement of nitric oxide-related amino acids in serum and plasma: effects of blood clotting and type of anticoagulant.
    Davids M; Peters JH; de Jong S; Teerlink T
    Clin Chim Acta; 2013 Jun; 421():164-7. PubMed ID: 23518295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of anticoagulants for serologic assays of cholera vaccination.
    Yang JS; Kang SS; Yun CH; Han SH
    Clin Vaccine Immunol; 2014 Jun; 21(6):854-8. PubMed ID: 24717970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Directed polyvalent display of sulfated ligands on virus nanoparticles elicits heparin-like anticoagulant activity.
    Mead G; Hiley M; Ng T; Fihn C; Hong K; Groner M; Miner W; Drugan D; Hollingsworth W; Udit AK
    Bioconjug Chem; 2014 Aug; 25(8):1444-52. PubMed ID: 24960223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticoagulant-dependent in vitro hemagglutination in a cat.
    Schaefer DM; Priest H; Stokol T; Goldstein RE; Belcher N
    Vet Clin Pathol; 2009 Jun; 38(2):194-200. PubMed ID: 19490570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.